This article first appeared on TCSDaily.com.

This piece first appeared on HuffingtonPost.com.

A piece by Cornelia Kean in the May 2007 Pharmacy Practice News quotes ACSH's Dr. Gilbert Ross on direct-to-consumer drug ads:

This article first appeared on HuffingtonPost.com.

A Lancet article by Carol E. Gartner et al published online on May 10, 2007 cited the ACSH study "Tobacco Harm Reduction," which in turn appeared in Harm Reduction Journal (2006;3:37) and was the basis of ACSH's booklet on smokeless tobacco as harm reduction. The Lancet article concludes:

This item first appeared on HuffingtonPost.com.

I've been told by many that you haven't experienced a mango until you've had one from India. But until this week, you'd have had to travel pretty far to get one.

Many smokers are unable to quit smoking through complete nicotine and tobacco abstinence, and conventional quit-smoking programs generally present smokers with two unpleasant alternatives: quit or die.

An April 30, 2007 item by David E. Williams criticized a Wall Street Journal letter by ACSH's Todd Seavey that defended drug patents:
Todd Seavey from the American Council on Science and Health has himself worked up into a lather about Thailand’s willingness to break drug company patents to cut its spending on AIDS drugs ("Drug Patent Violations, Knock-Offs Harm Us All")...

New York, NY -- May 1, 2007. The public health establishment has misled smokers about the benefits and risks of using smokeless tobacco as a method of quitting cigarettes.

I was surprised that the authors of "Finding More Cancer Isn't the Answer" [April 10] didn't note the current controversy over screening CT exams for early detection of lung cancer. The same paradigm applies. The studies on the efficacy of screening those at high risk -- smokers and ex-smokers -- have concluded that, despite increased detection of small cancers and increased time of survival from detection, actual mortality has not been significantly reduced.